Edition:
United States

XBiotech Inc (XBIT.OQ)

XBIT.OQ on NASDAQ Stock Exchange Global Select Market

3.27USD
4:00pm EDT
Change (% chg)

$-0.07 (-2.10%)
Prev Close
$3.34
Open
$3.23
Day's High
$3.45
Day's Low
$3.17
Volume
7,986
Avg. Vol
40,907
52-wk High
$5.80
52-wk Low
$2.13

Chart for

About

XBiotech Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of different diseases. It focuses on its lead product candidate, Xilonix (MABp1), which is derived from a natural human immune response. The Company has also... (more)
No analyst recommendations are available for .

Overall

Beta: 0.60
Market Cap(Mil.): $115.34
Shares Outstanding(Mil.): 35.82
Dividend: --
Yield (%): --

Financials

  XBIT.OQ Industry Sector
P/E (TTM): -- 119.85 32.14
EPS (TTM): -0.68 -- --
ROI: -37.57 1.96 12.83
ROE: -37.58 1.12 14.95

BRIEF-XBiotech Announces First Patient In Phase 2 Study Evaluating Patients With Atopic Dermatitis

* XBIOTECH ANNOUNCES FIRST PATIENT IN PHASE 2 STUDY EVALUATING MABP1 IN PATIENTS WITH ATOPIC DERMATITIS Source text for Eikon: Further company coverage:

May 22 2018

BRIEF-XBiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

BRIEF-Xbiotech Announces Upcoming Phase 2 Clinical Studies In Dermatology

* XBIOTECH ANNOUNCES UPCOMING PHASE 2 CLINICAL STUDIES IN DERMATOLOGY

Apr 16 2018

Earnings vs. Estimates